Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on August 4, 2016. The filing serves to announce the company's financial and operational results for the quarter ended June 30, 2016. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1), which is not part of the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that results for the quarter ended June 30, 2016, were announced.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It notes that the information in this report and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 Press Release, as they are absent from the 8-K cover text.
- Confirm the company name is PharmAthene, Inc., noting the discrepancy with the "Altimmune, Inc." label in the request metadata.
- Review the press release for any updates on clinical trial progress or operational milestones for the second quarter of 2016.
- Check subsequent filings to see if the press release was later incorporated by reference into other SEC documents.